Education
About Us
Working with TipRanks
Follow Us
Biontech Se Sponsored Adr (BNTX)
:BNTX
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$81.20 - $129.27
Previous CloseN/A
Volume316.50K
Average Volume (3M)1.12M
Market Cap
$25.28B
Enterprise Value$9.88B
Total Cash (Recent Filing)$14.04B
Total Debt (Recent Filing)$269.60M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 03, 2025EPS Estimate
-1.2Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding240,398,730
10 Day Avg. Volume664,720
30 Day Avg. Volume1,117,218
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.36
Price to Sales (P/S)9.62
P/FCF Ratio-108.15
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue3.43
Enterprise Value/Gross Profit4.30
Enterprise Value/Ebitda-43.41
Forecast
1Y Price Target
$134.07Price Target Upside27.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Innovation And Future ProspectsManagement highlighted major infrastructure investments such as Kyber supercomputer and advanced generative biology models which could reshape how BNTX approaches immunotherapy design and optimization.
Investment And DevelopmentBioNTech's AI Day helped investors understand the tangible benefits of their investment in InstaDeep.
Technological AdvancementsNucleotide Transformer and InstaNovo platforms could help with faster genome exploration and protein development, giving BioNTech a competitive advantage.
Bears Say
Market CompetitionIncreased scrutiny is anticipated for pumitamig readouts due to negative competitor readouts from Summit, affecting BNTX stock movement.
Stock PerformanceBNTX's stock experienced a significant decline attributed to Summit's HARMONi readout.
BioNTech SE News
BNTX FAQ
What was Biontech Se Sponsored Adr’s price range in the past 12 months?
Biontech Se Sponsored Adr lowest stock price was $81.20 and its highest was $129.27 in the past 12 months.
What is Biontech Se Sponsored Adr’s market cap?
Biontech Se Sponsored Adr’s market cap is $25.28B.
When is Biontech Se Sponsored Adr’s upcoming earnings report date?
Biontech Se Sponsored Adr’s upcoming earnings report date is Nov 03, 2025 which is in 26 days.
How were Biontech Se Sponsored Adr’s earnings last quarter?
Biontech Se Sponsored Adr released its earnings results on Aug 04, 2025. The company reported -$1.872 earnings per share for the quarter, beating the consensus estimate of -$2.671 by $0.799.
Is Biontech Se Sponsored Adr overvalued?
According to Wall Street analysts Biontech Se Sponsored Adr’s price is currently Undervalued.
Does Biontech Se Sponsored Adr pay dividends?
Biontech Se Sponsored Adr pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on Biontech Se Sponsored Adr dividends here
What is Biontech Se Sponsored Adr’s EPS estimate?
Biontech Se Sponsored Adr’s EPS estimate is -1.2.
How many shares outstanding does Biontech Se Sponsored Adr have?
Biontech Se Sponsored Adr has 240,398,730 shares outstanding.
What happened to Biontech Se Sponsored Adr’s price movement after its last earnings report?
Biontech Se Sponsored Adr reported an EPS of -$1.872 in its last earnings report, beating expectations of -$2.671. Following the earnings report the stock price went up 2.506%.
Which hedge fund is a major shareholder of Biontech Se Sponsored Adr?
Currently, no hedge funds are holding shares in BNTX
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$134.07 (27.49% Upside)
$134.07 (27.49% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 275.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $277.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
-1.81%
Trailing 12-Months
Asset Growth
6.57%
Trailing 12-Months
Company Description
Biontech Se Sponsored Adr
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX Company Deck
BNTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with notable increases in revenue and strategic collaborations, particularly the landmark deal with BMS. However, the company reported a net loss and anticipated lower COVID-19 vaccination rates, which presented challenges.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$134.07
▲(27.49% Upside)
Technical Analysis
Ownership Overview
0.43% Insiders
5.84% Mutual Funds
13.92% Other Institutional Investors
78.78% Public Companies and
Individual Investors